NCT07670871Not yet recruiting
Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
The EXPAND study is a prospective observational study designed to investigate the biological mechanisms underlying the heterogeneity of type 2 diabetes and related metabolic disorders. The study will enroll adults with and without pancreatic disease, including patients undergoing pancreatic surgery, individuals with chronic pancreatitis, subjects at high risk of type 2 diabetes, and patients with newly diagnosed type 2 diabetes. Clinical, metabolic, imaging, genetic, microbiome, and molecular data will be integrated to identify distinct metabolic endotypes and to investigate the interactions between the exocrine pancreas, endocrine pancreas, and adipose tissue. The ultimate goal is to improve the understanding of diabetes pathophysiology and support the development of precision medicine approaches.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 440 (estimated)
- First submitted
- 22 Jun 2026
- Start date
- Sept 2026
- Primary completion date
- Nov 2029
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Pancreatic cancer, Type 2 diabetes
- NCT number
- NCT07670871
What you commit to
- Study type: Observational
- Planned participants: 440
- From Sept 2026 to the primary completion date, Nov 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another interventional clinical trial involving an investigational medicinal product within 30 days before enrollment.
Other illness
- Diagnosis of type 1 diabetes mellitus.
- Clinical conditions that preclude completion of the planned metabolic assessments.
Age
- Age \<20 years or \>78 years.
Other
- Inability or unwillingness to provide informed consent.
- Pregnancy or breastfeeding.
- Inability to comply with study procedures.
Who the study is looking for
- Adults aged 20 to 78 years.
- Ability and willingness to provide written informed consent.
- Eligibility for one of the study cohorts:
- Individuals undergoing pancreatectomy for non-endocrine pancreatic disease.
- Individuals with pancreatic ductal adenocarcinoma undergoing pancreatectomy.
- Individuals with chronic pancreatitis or a previous episode of acute pancreatitis.
- Individuals at increased risk of type 2 diabetes mellitus, including impaired fasting glucose and/or impaired glucose tolerance.
- Individuals with newly diagnosed type 2 diabetes mellitus.
- Ability to undergo study-related metabolic assessments and sample collection procedures.
Age in the registry: 20 years to 78 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.